Gelteq Ltd. has announced positive results from a recently completed preclinical study evaluating the delivery of medicinal cannabinoids using its proprietary oral gel platform. The study demonstrated that the oral gel significantly enhances the absorption and bioavailability of cannabidiol $(CBD)$ compared to an existing FDA-approved oil-based product. The results have already been presented. According to the company, this advancement could support accelerated partnerships and product launches, including licensing and co-development opportunities with medicinal cannabis companies, and may facilitate faster market entry through the Australian government's SAS program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gelteq Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9624516) on January 13, 2026, and is solely responsible for the information contained therein.